YUE DA INTL (00629) Subsidiary Yue Da Commercial Factoring and Binhai Economic Development entered into a factoring agreement.
Yuanda International Holdings (00629) announced that on December 19, 2025, its indirectly wholly-owned subsidiary Yuanda Commercial Factoring entered into a factoring agreement with Binhai Development (Binhai Development Factoring Agreement). According to the Binhai Development Factoring Agreement, Yuanda Commercial Factoring agreed to provide accounts receivable financing, accounts receivable management services, and accounts receivable collection services (accounts receivable services) to Binhai Development, and granted a revolving credit limit of RMB 50 million, with an annual interest rate and factoring management fee totaling 8% to 9%, effective from December 19, 2025, and maturing on December 23, 2026.
YUE DA INTL (00629) announces that on December 19, 2025, its indirect wholly-owned subsidiary, YueDa Commercial Factoring, has entered into a factoring agreement with BinHai JingFa Economic Development Company Limited (BinHai JingFa Factoring Agreement).
Under the BinHai JingFa Factoring Agreement, YueDa Commercial Factoring agrees to provide accounts receivable financing, accounts receivable management services, and accounts receivable collection services (accounts receivable services) to BinHai JingFa, and grants a revolving credit limit of RMB 50 million. The annual interest rate and factoring management fee combined is 8% to 9%, effective from December 19, 2025, and expiring on December 23, 2026.
Related Articles
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
